Ahead of the Curve: Early Interventions for Delaying Type 1 Diabetes - Episode 6

Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1

, , ,

Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.

EP. 1: Assessing the Burden of Type 1 Diabetes
EP. 2: Guidelines for Type 1 Diabetes Screening
EP. 3: Defining the Stages of Type 1 Diabetes
EP. 4: Impact of Delayed Intervention In Stage 2 Type 1 Diabetes
EP. 5: Screening for Autoantibodies in Type 1 Diabetes
Now Viewing
EP. 6: Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1
EP. 7: Clinical Trial Data for Teplizumab
EP. 8: Patient Selection for Teplizumab and Infusion Process

Related Content:

Ahead of the Curve: Early Interventions for Delaying Type 1 Diabetes Video SeriesDiabetes
Patient Cases Highlighting Integration of OSA Treatments into Practice
Alternative Treatments for OSA
Treatments for OSA With a Focus on PAP Therapy as the Gold Standard